Register or Sign in to Save this opportunity, or Send an Inquiry.
Composition for Stimulating Erythropoiesis Comprising Quercetin 3-O-?-(2?-galloyl)-rhamnopyranoside As Active Ingredient_Chungbuk Univ.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Composition for Stimulating Erythropoiesis Comprising Quercetin 3-O-?-(2?-galloyl)-rhamnopyranoside As Active Ingredient
Send an Inquiry
RE:
Participants
You

Technology Overview


 


3-O-β-(2"-galloyl)-rhamnopyranoside(QGR) ? Stimulating erythropoiesis


 


Erythropenia treat, improvement, prophylaxis.


 


 


 


Background and unmet needs


 


Anemia is a decrease in number of red blood cells(RBCs) or less than the nomal quantity of hemoglobin in the blood. In severe anemia, there may be signs of a hyperdynamic circulation: tachycardia, bounding pulse, flow murmurs, and cardiac ventricular hypertrophy.


 


3-O-β-(2"-galloyl)-rhamnopyranoside(QGR) is the polyphenol compound isolated from Persicaria lapathifolia. Pure ingredient QGR from Persicaria lapathifolia has an antiinflammatory effect. Little has known about stimulating erythropoiesis in QGR.


 


 


 


Discovery and Achievements


 


The erythropoietic potential of QGR in mouse bone marrow mononuclear cells (BMNCs) are examined. BMNCs including hematopoietic stem cells (HSCs), early progenitor cells (EPCs), stromal cells and other precursor cells were isolated from femurs and tibias of 8 to 12-week-old male C57BL/6 mice. QGR significantly increased the cell viability of BMNCs even in hypoxic condition, and mRNA expressions of stem cell factor, granulocyte macrophage-colony stimulating factor and erythropoietin from bone marrow stromal cells. In a colonogenic assay, formation of burst forming unit-erythroid colony was enhanced by QGR treatment. Immunocytochemistry and flow cytometry against TER-119, a surface marker of erythroid precursor cells revealed that QGR enhanced the number of positive cells. QGR has erythropoietic effect by activating the differentiation of HSCs or EPCs in early stages of hematopoiesis.

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated Aug 2017
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
GOVERNMENT INSTITUTE

Opportunity Contact